These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 35978659)
1. Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions. Lanzaro F; Guarino S; D'Addio E; Salvatori A; D'Anna JA; Marzuillo P; Miraglia Del Giudice E; Di Sessa A World J Hepatol; 2022 Jun; 14(6):1087-1098. PubMed ID: 35978659 [TBL] [Abstract][Full Text] [Related]
2. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults. Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318 [TBL] [Abstract][Full Text] [Related]
3. The Gut Microbiome and Ferroptosis in MAFLD. Ji J; Wu L; Wei J; Wu J; Guo C J Clin Transl Hepatol; 2023 Feb; 11(1):174-187. PubMed ID: 36406312 [TBL] [Abstract][Full Text] [Related]
4. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus. Bhardwaj M; Mazumder PM Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38861011 [TBL] [Abstract][Full Text] [Related]
5. Pediatric metabolic (dysfunction)-associated fatty liver disease: current insights and future perspectives. Vimalesvaran S; Vajro P; Dhawan A Hepatol Int; 2024 Jun; ():. PubMed ID: 38879851 [TBL] [Abstract][Full Text] [Related]
6. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. Sun DQ; Targher G; Byrne CD; Wheeler DC; Wong VW; Fan JG; Tilg H; Yuan WJ; Wanner C; Gao X; Long MT; Kanbay M; Nguyen MH; Navaneethan SD; Yilmaz Y; Huang Y; Gani RA; Marzuillo P; Boursier J; Zhang H; Jung CY; Chai J; Valenti L; Papatheodoridis G; Musso G; Wong YJ; El-Kassas M; Méndez-Sánchez N; Sookoian S; Pavlides M; Duseja A; Holleboom AG; Shi J; Chan WK; Fouad Y; Yang J; Treeprasertsuk S; Cortez-Pinto H; Hamaguchi M; Romero-Gomez M; Al Mahtab M; Ocama P; Nakajima A; Dai C; Eslam M; Wei L; George J; Zheng MH Hepatobiliary Surg Nutr; 2023 Jun; 12(3):386-403. PubMed ID: 37351121 [TBL] [Abstract][Full Text] [Related]
7. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us. Grabherr F; Grander C; Effenberger M; Schwärzler J; Tilg H Ther Adv Endocrinol Metab; 2022; 13():20420188221139101. PubMed ID: 36439029 [TBL] [Abstract][Full Text] [Related]
8. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective. Nardolillo M; Rescigno F; Bartiromo M; Piatto D; Guarino S; Marzuillo P; Miraglia Del Giudice E; Di Sessa A World J Gastroenterol; 2024 Apr; 30(15):2081-2086. PubMed ID: 38681989 [TBL] [Abstract][Full Text] [Related]
9. Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge. Fouda S; Pappachan JM Endocrinol Metab Clin North Am; 2023 Sep; 52(3):xv-xvi. PubMed ID: 37495346 [TBL] [Abstract][Full Text] [Related]
10. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW; Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877 [TBL] [Abstract][Full Text] [Related]
11. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. Yang K; Song M Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764755 [TBL] [Abstract][Full Text] [Related]
13. Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Wong VW; Wong GL; Woo J; Abrigo JM; Chan CK; Shu SS; Leung JK; Chim AM; Kong AP; Lui GC; Chan HL; Chu WC Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2161-2171.e5. PubMed ID: 33137486 [TBL] [Abstract][Full Text] [Related]
14. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health. Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329 [TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches. Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033 [TBL] [Abstract][Full Text] [Related]
17. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060 [TBL] [Abstract][Full Text] [Related]
18. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Lim S; Kim JW; Targher G Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804 [TBL] [Abstract][Full Text] [Related]
19. MAFLD: Renovation of clinical practice and disease awareness of fatty liver. Kawaguchi T; Tsutsumi T; Nakano D; Torimura T Hepatol Res; 2022 May; 52(5):422-432. PubMed ID: 34472683 [TBL] [Abstract][Full Text] [Related]
20. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Le Garf S; Nègre V; Anty R; Gual P Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]